Mariner
DSGN icon

Mariner’s Design Therapeutics DSGN Stock Holding History

Mariner’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,066
Closed -$139K – 3615
2026
Q1 		$139K Buy
13,066
+244
+2% +$2.47K ﹤0.01% 3260
2025
Q4 		$120K Sell
12,822
-3,259
-20% -$25.5K ﹤0.01% 3296
2025
Q3 		$121K Buy
16,081
+341
+2% +$1.71K ﹤0.01% 3323
2025
Q2 		$53K Buy
15,740
+269
+2% +$1.01K ﹤0.01% 3340
2025
Q1 		$59.7K Sell
15,471
-786
-5% -$3.75K ﹤0.01% 3280
2024
Q4 		$100K Buy
16,257
+129
+0.8% +$747 ﹤0.01% 3189
2024
Q3 		$86.7K Sell
16,128
-2,546
-14% -$12K ﹤0.01% 3115
2024
Q2 		$62.6K Hold
18,674
– – ﹤0.01% 3019
2024
Q1 		$75.3K Buy
+18,674
New +$49.9K ﹤0.01% 2978

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mariner's DSGN Position: Q2 2026 in Review

Mariner sold out of Design Therapeutics (DSGN) in Q2 2026, closing a stake of 13,066 shares — an estimated $139K sold.

Mariner first reported a position in DSGN in Q1 2024 and held it in 9 quarters. The position peaked at $139K in Q1 2026. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Mariner reported no remaining Design Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Mariner sold 13,066 Design Therapeutics shares in Q2 2026, an estimated $139K.
  • Mariner first reported a position in Design Therapeutics in Q1 2024 and held it in 9 quarters.
  • Mariner's Design Therapeutics position peaked at $139K in Q1 2026.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.